It is our hope that the present work will spur future application of EGCG as a Bmal1-targeting compound to mitigate redox status imbalance and circadian rhythm disorders-related pathologies, such as IDD. The gene discussed is BMAL1; the disease is intervertebral disk degenerative disorder.